Food Does Not Influence the Pharmacokinetics of a New Extended Release Formulation of Tolterodine for Once Daily Treatment of Patients with Overactive Bladder

Author： Olsson B.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.40, Iss.2, 2001-01, pp. : 135-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release Tolterodine

By Olsson B.  

Clinical Pharmacokinetics, Vol. 40, Iss. 3, 2001-01 ,pp. : 227-235

Adis International

Access to resources Recommend Favorite

Extended-release tolterodine is an effective and convenient option in the treatment of overactive bladder

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 2, 2005-02 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Tolterodine for the treatment of overactive bladder

By Salvatore Stefano   Serati Maurizio   Bolis Pierfrancesco  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 7, 2008-05 ,pp. : 1249-1255

Informa Healthcare

Access to resources Recommend Favorite

Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease

By Perez Lloret Santiago   Rascol Olivier  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 13, 2010-09 ,pp. : 2221-2230

Informa Healthcare

Access to resources Recommend Favorite

Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment: An Open-Label, Flexible-Dosing, Multicentre Study

By Swift Steven E.  

Clinical Drug Investigation, Vol. 29, Iss. 5, 2009-01 ,pp. : 305-316

Adis International

Access to resources Recommend Favorite